With 1.22 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.9899 whereas the lowest price it dropped to was $1.47. The 52-week range on TRAW shows that it touched its highest point at $19.44 and its lowest point at $0.97 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 1.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TRAW was up-trending over the past week, with a rise of 9.46%, but this was up by 2.53% over a month. Three-month performance surged to 30.65% while six-month performance fell -76.49%. The stock lost -81.76% in the past year, while it has lost -82.25% so far this year.
Float and Shares Shorts:
At present, 7.07 million TRAW shares are outstanding with a float of 4.61 million shares on hand for trading. On 2025-07-31, short shares totaled 96639.0, which was 173.99999999999997 higher than short shares on 1751241600. In addition to Dr. Victor Moyo M.D. as the firm’s Chief Medical Officer of Oncology, Dr. Iain D. Dukes DPHIL, M.A., Ph.D. serves as its Interim CEO, Secretary & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, TRAW reported revenue of $57000.0 and operating income of -$5203000.0. The EBITDA in the recently reported quarter was -$31715000.0 and diluted EPS was $2.09.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$154.35 being high and -$154.35 being low. For TRAW, this leads to a yearly average estimate of -$154.35.
